Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20020182623 A1
Publication typeApplication
Application numberUS 10/081,118
Publication dateDec 5, 2002
Filing dateFeb 25, 2002
Priority dateFeb 23, 2001
Also published asCA2372608A1, CN1220057C, CN1385701A, DE60238455D1, EP1239283A1, EP1239283B1, US7638290, US20070111276
Publication number081118, 10081118, US 2002/0182623 A1, US 2002/182623 A1, US 20020182623 A1, US 20020182623A1, US 2002182623 A1, US 2002182623A1, US-A1-20020182623, US-A1-2002182623, US2002/0182623A1, US2002/182623A1, US20020182623 A1, US20020182623A1, US2002182623 A1, US2002182623A1
InventorsDidier Lefevre, Sylvie Veriac, Henri Champseix
Original AssigneeDidier Lefevre, Sylvie Veriac, Henri Champseix
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Reagent and process for the identification and counting of biological cells
US 20020182623 A1
Abstract
The invention relates to a reagent and a process for the identification and counting of biological cells in a sample. This reagent comprises a cell lysing agent selected from at least one detergent in a concentration capable of specifically lysing a given type of cells in the sample, and a stain capable of marking the intracellular nucleic acids of the remaining unlysed cells. Application in particular for the identification and counting of cells using an automated analysis system based on flow cytometry.
Images(4)
Previous page
Next page
Claims(18)
1. Reagent for the identification and counting of biological cells in a sample, in particular in a blood sample, characterised in that it comprises:
a cell lysing agent selected from at least one detergent in a concentration sufficient to lye specifically a given type of cell in the sample, and
a stain designed to mark the intracellular nucleic acids of the unlysed remaining cell.
2. Reagent according to claim 1, characterised in that the cell lysing agent comprising at least one ionic and/or non-ionic detergent in a concentration capable of lysing erythrocytes.
3. Reagent according to claim 1, characterised in that the detergent is selected from:
primary amines, amine acetates and hydrochlorides, quaternary ammonium salts, and trimethylethyl ammonium bromide;
amides of substituted diamines, diethanolaminopropylamine or diethylaminopropylamide, amides of cyclised diethylenetriamine;
alkylaryl sulfonates, petroleum sulfonates, sulfonated glycerides;
cholamides, sulfobetaines;
alkyl glycosides, saponins;
polyoxyethylene ethers and sorbitans, polyglycol ethers.
4. Reagent according to claim 1, characterised in that the stain is a fluorescent type stain.
5. Reagent according to claim 1, characterised in that the stain is capable of combining specifically with the intracellular ribonucleic acid and enhancing its fluorescence once it has combined with the latter.
6. Reagent according to claim 1, characterised in that the stain is selected from:
thiazole orange or 1-methyl-4-[(3-methyl-2-(3H)-benzothiazolylidene)methyl]quinolinium p-tosylate,
thiazole blue,
4-[(3-methyl-2-(3H)-benzothiazolyl-idene)methyl]-1-[3-(trimethylammonium)propyl]quinolinium diiodide,
3,3′-dimethyloxacarbocyanine iodide or 3-methyl-2-[3-(3-methyl-2(3H)-benzothiazolylidene-1-propenyl]benzoxazolium iodide,
thioflavine T,
thioflavine T,
the stains SYTOŽ and TOTOŽ (TM Molecular Probes),
ethidium bromide,
propidium iodide,
acridine orange,
coriphosphine O,
auramine O,
the stains HOECHST 33258 and HOECHST 33342,
4′,6-diamino-2-phenylindole dihydrochloride (DAPI),
4′,6-(diimidazolin-2-yl)-2-phenylindole dihydrochloride (DIPI),
7-aminoactinomycin D,
actinomycin D, and
LDS 751.
7. Reagent according to claim 1, characterised in that it also comprises at least one membrane penetration agent capable of promoting the penetration of the stain into the cells to be marked.
8. Reagent according to claim 7, characterised in that the agent promoting membrane penetration is an ionophore compound of the protonophore and/or antibiotic type.
9. Reagent according to claim 1, characterised in that it also comprises at least one membrane fixing agent present in a concentration of 0.1% to 10% (w/v).
10. Reagent according to claim 9, characterised in that the membrane fixing agent comprises at least one alcohol and/or an aldehyde selected from paraformaldehyde and glutaraldehyde.
11. Reagent according to claim 1, characterised in that it also comprises at least one compound selected from a complexing agent, an inorganic salt and a buffer system.
12. Process for the identification and counting of biological cells in a sample, in particular in a blood sample, characterised in that it comprises the following operations:
mixing and incubating the sample with a reagent according to one of claims 1 to 11 in order to effect, in a single stage, the lysis of cells of a given type, in particular erythrocytes, the staining of the intracellular nucleic acids, and the fixing of the nucleate cells;
measuring the resultant solution by flow cytometry using at least two measuring parameters selected from resistive volume, axial luminous diffraction, axial luminous transmission, orthogonal luminous transfusion, and fluorescence; and
classifying and counting the nucleate cells in populations by means of the measured parameters.
13. Process according to claim 12, characterised in that the resistivity measurement is carried out by means of at least one current selected from a continuous current and a pulsed or alternating current.
14. Process according to claim 12, characterised in that the axial luminous diffraction parameter is at least one parameter selected from small angle diffraction and large angle diffraction.
15. Process according to claim 12, characterised in that the classified nucleate cells are either mature or immature, normal or abnormal cells.
16. Process according to claim 12, characterised in that the classification of the nucleate cells is carried out by means of a multidimensional analysis software program, with or without the use of a software or other neuronal technique.
17. Process according to claim 12, characterised in that the sample is a sample of human or animal blood.
18. Process according to claim 12, characterised in that the sample is a sample of biological fluid or a suspension of cells of human or animal origin.
Description
FIELD OF THE INVENTION

[0001] The present invention relates to biological analyses and in particular to blood analyses.

[0002] The invention relates more particularly to a reagent and a process for the identification and counting of biological cells in a sample, in particular in a blood sample.

[0003] The biological sample may be human or animal blood, or also any other biological liquid or biological preparation.

BACKGROUND OF THE INVENTION

[0004] In the field of biological analyses the importance of the determination and precise counting of different cell populations in making a diagnosis has been recognised for a long time. In fact, the appearance of abnormal equilibrium ratios among normal cell populations in blood may be correlated with the appearance of certain medical conditions, for example immune reactions, inflammatory reactions, etc. Similarly, the appearance of abnormal cell populations may also be correlated with the appearance of other conditions, such as leukaemia, etc.

[0005] There are various conventional methods of cytological analysis, involving microscopic examination after staining, and if necessary after sedimentation or aggregation. The automatic determination of blood cells began at the beginning of the 1960s with the separation of the main normal leucocyte populations; see the following bibliographic reference: (1) Hallerman L., Thom R., Gerhartz H. : “Elecktronische Differentialzählzung von Granulocyten and Lymphocyten nach intervaler Fluochromierung mit Acridinorange” (“Electronic Differential Counting of Granulocytes and Lymphocytes by Interval Fluorochrome Staining with Acridine Orange”), Verh Deutsch Ges Inn Med 70: 217, 1964.

[0006] The separation of the leucocytes was performed by flow cytometry utilising various principles involving the optical and chemical properties of the cells. Several automated haematology analysers have been produced, using various techniques such as Coulter's principle for determining volumes, measurement of diffracted light for estimating sizes, measurement of diffused light at 90° for determining the internal structures of cells, and fluorescence or absorption measurements for determining the affinities of cells for various stains; see the following bibliographic references 2 to 5:

[0007] (2) Adams L. R., Kamensky L. A.: “Fluorometric Characterization of Six Classes of Human Leukocytes” Acta Cytol 18: 389, 1974;

[0008] (3) Shapiro H. M. et al. “Combined Blood Cell Counting and Classification with Fluorochrome Stains and Flow Instrumentation” J. Histochem Cytochem 24: 396-411, 1976;

[0009] (4) Terstappen L. W. et al. “Multidimensional Flow Cytometric Blood Cell Differentiation Without Erythrocyte Lysis” Blood Cells 17: 585-602, 1991;

[0010] (5) Terstappen L. W., Levin J. “Bone marrow cell differential counts obtained by multidimensional flow cytometry” Blood Cells 18 (2): 311-30, 1992.

[0011] The characterisation of cells in early stages of the cell cycle has long been of interest to scientists and the quantification of the RNA content of each cell has for a long time been recognised as a representative parameter of this cycle; see the bibliographic references 2 to 5 above and the following bibliographic references 6 and 7: (6) Traganos F., Darzynkiewicz Z., Sharpless T., Melamed M. R. “Simulataneous Staining of Ribonucleic and Deoxyribonucleic Acids in Unfixed Cells Using Acridine Orange in a Flow Cytofluorometric System” J. Histochem Cytochem 25: 46, 1977; (7) Pollack A. et al. “Flow Cytometric Analysis of RNA Content in Different Cell Populations Using Pyronin Y and Methyl Green” Cytometry, vol. 3, no. 1, pages 28-35, 1982.

[0012] In their French patent no. 97 01090, dated Jan. 31, 1997 the Applicants have already described a composition, and more particularly a staining reagent, enabling this type of analysis to be performed.

[0013] In order to automate such techniques various problems first of all have to be solved, in particular reducing the treatment times and cost of preparing the samples. Such a reduction may be achieved in various ways, the most obvious being to reduce the number of channels so that only one cell preparation is carried out at any one time. This type of technique has previously been described by Léon W. Terstappen (reference 4 above), but requires a long treatment and analysis time, in particular for the accurate counting of the nucleate cells, the number of which is often a thousand times less than the number of erythrocytes.

[0014] In order to obviate this difficulty the biological sample is often separated into at least two aliquot parts, one of which is prepared at a certain concentration enabling the erythrocytes and platelets to be studied, the other being prepared at a higher concentration for the analysis of the nucleate cells.

[0015] These known techniques have various disadvantages.

[0016] Before the analysis, the treatment of this aliquot part often involves the specific destruction of the erythrocytes in order to facilitate the measurement of the remaining cells. Although such a method enables the results of the measurements to be obtained more quickly, this is nevertheless offset by the time involved in the reaction, transfer and staining in order to obtain the desired preparation.

[0017] The incubation time of a cell suspension in a reagent solution is in particular associated with the time required for the active principles to penetrate the interior of the cells. In French patent no. 97 01090 mentioned hereinbefore, the Applicants have described ways of accelerating this penetration involving the use of an additive, in particular an ionophore type additive, to assist the cell penetration.

[0018] The treatment time is also a function of the number of successive stages that the aliquot part has to pass through. Lysis and staining of the cells are often carried out in two successive stages, in one order or the other (see U.S. Pat. No. 6,004,816).

[0019] These two dilution stages involve a not inconsiderable expenditure in material, associated with a long minimum treatment time.

BRIEF SUMMARY OF THE INVENTION

[0020] An object of the present invention is accordingly to provide a reagent for the identification and counting of biological cells that avoids the aforementioned disadvantages.

[0021] An object of the present invention is in particular to provide such a reagent that enables the lysis of certain cells, in particular erythrocytes, the fixing of the nucleate cells and the staining of the intracellular material to be carried out simultaneously.

[0022] An object of the present invention is also to provide such a reagent that enables these operations to be carried out in a conveniently short time in order to reduce to a large extent the cost and time of the analysis and the number of reagents involved.

[0023] The invention accordingly provides a reagent for the identification and counting of biological cells in a sample, the said reagent comprising:

[0024] a cell lysing agent selected from at least one detergent in a concentration sufficient to lyse specifically a given type of cell in the sample, and

[0025] a stain designed to mark the intracellular nucleic acids of the remaining unlysed cell.

[0026] The invention thus provides a reagent for the simultaneous lysing and staining of a biological sample, enabling a solution of cells to be obtained in a single stage that can be analysed by for example a flow cytometry system. This analysis enables the thus treated cells to be classified and counted.

[0027] The reagent of the invention accordingly combines a reagent solution of the type described in French patent no. 97 01090 with a cell lysing agent that enables a given type of cells of the sample, in particular erythrocytes, to be specifically lysed.

[0028] The staining reagent solution per se, described in French patent no. 97 01090, enables the membrane permeation to be accelerated for the subsequent staining of the biological cells of the sample. This staining solution may be used before as well as after the lysing of the erythrocytes, depending on the types of cells being studied. The reagent principle of this staining solution is thus preserved and introduced into a lysing solution, enabling the erythrocytes to be destroyed and the remaining cells to be stained before they are counted.

[0029] The cell lysing agent advantageously includes at least one ionic and/or non-ionic detergent in a concentration capable of lysing erythrocytes.

[0030] The detergent of the invention is advantageously selected from:

[0031] primary amines, amine acetates and hydrochlorides, quaternary ammonium salts, and trimethylethyl ammonium bromide;

[0032] amides of substituted diamines, diethanolaminopropylamine or diethylaminopropylamide, amides of cyclised diethylenetriamine;

[0033] alkylaryl sulfonates, petroleum sulfonates, sulfonated glycerides;

[0034] cholamides, sulfobetaines;

[0035] alkyl glycosides, saponins;

[0036] polyoxyethylene ethers and sorbitans, polyglycol ethers.

[0037] In one embodiment this detergent comprises a mixture of Triton X100 in a concentration of 0.05% (w/v) and Tween 20 in a concentration of 0.0001% (v/v).

[0038] Throughout the description the expression “w/v” denotes “weight/volume” and the expression “v/v” denotes “volume/volume”.

[0039] The stain that is used is advantageously of the fluorescent type.

[0040] Advantageously a stain is selected that is capable of combining specifically with the intracellular ribonucleic acid and enhancing its fluorescence once it has combined with the latter.

[0041] The stain of the invention may be selected in particular from the following stains:

[0042] thiazole orange or 1-methyl-4-[(3-methyl-2-(3H)-benzothiazolylidene)methyl]quinolinium p-tosylate,

[0043] thiazole blue,

[0044] 4-[(3-methyl-2-(3H)-benzothiazolyl-idene)methyl]-1-[3-(trimethylammonium)propyl]quinolinium diiodide,

[0045] 3,3′-dimethyloxacarbocyanine iodide or 3-methyl-2-[3-(3-methyl-2(3H)-benzothiazolylidene -1-propenyl]benzoxazolium iodide,

[0046] thioflavine T,

[0047] the stains SYTOŽ and TOTOŽ (TM Molecular Probes),

[0048] ethidium bromide,

[0049] propidium iodide,

[0050] acridine orange,

[0051] coriphosphine O,

[0052] auramine O,

[0053] the stains HOECHST 33258 and HOECHST 33342,

[0054] 4′,6-diamino-2-phenylindole dihydrochloride (DAPI),

[0055] 4′,6-(diimidazolin-2-yl)-2-phenylindole dihydrochloride (DIPI),

[0056] 7-aminoactinomycin D,

[0057] actinomycin D, and

[0058] LDS 751.

[0059] In a preferred embodiment of the invention the reagent moreover comprises at least one membrane penetration agent capable of promoting the penetration of the stain into the cells to be marked.

[0060] The agent promoting the membrane penetration is advantageously an ionophore compound of the protonophore and/or antibiotic type.

[0061] This agent is generally present in a concentration of less than 0.005% (w/v). An example of an antibiotic that can be used is valinomycin.

[0062] It is advantageous if the reagent moreover comprises at least one membrane fixing agent present in a concentration of 0.1% to 10% (w/v). This fixing agent preferably comprises at least one alcohol and/or one aldehyde. Paraformaldehyde or glutaraldehyde for example are preferably used for this purpose.

[0063] It is also possible within the scope of the invention to include other additives or components in the reagent.

[0064] This reagent may accordingly also comprise at least one compound selected from a complexing agent, an inorganic salt and a buffer system.

[0065] According to another aspect, the invention relates to a process for the identification and counting of biological cells in a sample, in particular in a blood sample, which process comprises the following operations:

[0066] mixing and incubating the sample with a reagent as defined above in order to effect, in a single stage, the lysis of cells of a given type, in particular erythrocytes, the staining of the intracellular nucleic acids, and the fixing of the nucleate cells;

[0067] measuring the resultant solution by flow cytometry using at least two measuring parameters selected from resistive volume, axial luminous diffraction, axial luminous transmission, orthogonal luminous transfusion, and fluorescence; and

[0068] classifying and counting the nucleate cells in populations by means of the measured parameters.

[0069] In the flow cytometry measurement the axial luminous diffraction parameter is at least one parameter selected from small angle diffraction and large angle diffraction.

[0070] This measurement may be carried out by means of a flow cytometer having the conventional parameters such as axial diffraction or “FSC” (forward scatter), orthogonal diffusion or “SSC” (side scatter), either orthogonal fluorescence (FL1), axial fluorescence or epi-fluorescence, all polarised or depolarised, as well as additional measuring parameters such as transmitted light measurement or resistive volume as described in French patent no. 89 14120 of Oct. 27, 1989.

[0071] The resistivity may be measured by means of a continuous current in order to express the volume of the elements and/or by means of a pulsed or alternating current in order to express the internal densimetric differences approximating to the determination of the structure.

[0072] These parameters may be used to obtain sets of multi-parameter data for each of the analysed cells, enabling the latter to be classified. The classification will be more precise the more relevant and numerous the parameters defining the cells. This type of multi-parameter study has already been described before (see the bibliographic references 4 and 5 above).

[0073] Within the scope of the invention the classified nucleate cells may either be mature or immature, or normal or abnormal cells.

[0074] The classification of nucleate cells is carried out by known processes. The classification may be performed by means of a multidimensional analysis software program, with or without the use of a software or other neuronal technique.

[0075] Within the scope of the invention the biological sample may be a sample of a human or animal blood, or also a sample of biological fluid or a suspension of cells of human or animal origin.

[0076] This sample is mixed with the reagent solution under specified temperature conditions. The reaction kinetics mean that the erythrocytes are first of all destroyed, the penetration of the stain being in parallel to the fixing of the cells, which takes place more slowly.

DETAILED DESCRIPTION OF THE INVENTION

[0077] The invention will now be described by reference to the following example:

EXAMPLE

[0078] Within the scope of this example a reagent is used having the following composition:

Complexing agent EDTA 0.02% (w/v)
Inorganic salt NaCl 0.85% (w/v)
Buffer system Phosphates 0.5% (w/v)
Detergents Triton X100 0.05% (w/v)
Tween 20 0.0001% (v/v)
Ionophore Valinomycin 0.003% (w/v)
Stain Thiazole orange 0.005% (w/v)
Aldehyde Paraformaldehyde 1% (w/v)

[0079] A sample of total blood is mixed with the above reagent solution. After an incubation of a few seconds (typically of the order of 15 to 30 seconds) the solution is analysed by means of a flow cytometry system comprising at least the following parameters: axial diffraction (FSC) providing an interpretation of the size, orthogonal diffusion (SSC) expressing the structure of the elements observed, and orthogonal fluorescence (FL1) enabling the expression of the intracellular ribonucleic acid to be measured.

[0080] The results thus obtained are observed in multidimensional mode so as to determine the interrelationships of the various populations among each parameter.

[0081] Reference will now be made to FIGS. 1 to 4, which show the results obtained with a sample of normal human blood.

[0082]FIG. 1 shows the matrix obtained by means of the two parameters, axial diffraction (FSC) and orthogonal diffusion (SSC). Four different populations can clearly be seen: L denotes lymphocytes, M denotes monocytes, N denotes polynuclear neutrophils, and E denotes polynuclear eosinophils. The populations IG of immature granulocytes, BL of blastocytes, B of polynuclear basophils and ErB of erythroblasts are shown but cannot be differentiated in only two dimensions.

[0083]FIG. 2 shows the matrix formed by the axial diffraction (FSC) and fluorescence (FLI) parameters. The same four populations as shown in FIG. 1 can be seen, but arranged differently. The mononucleate cells L and M form the upper group of average fluorescence, and the polymorphonucleate cells N, E and B form the lower group of weak fluorescence. The population ErB of erythroblasts is clearly separated at the apex of the two groups thus formed. The normal positions of the populations BL and IG are shown.

[0084]FIG. 3 shows the matrix formed by the orthogonal diffusion (SSC) and fluorescence (FL1) parameters. The same populations are found organised in a different way, but enabling the populations IG and BL to be isolated (in very small amounts in a normal sample).

[0085]FIG. 4 shows a three-dimensional representation of the populations obtained.

[0086]FIGS. 5 and 8 show the same types of results as FIGS. 1 to 4 respectively, but obtained with a sample containing blast cells (B1) and treated according to the invention.

[0087] FIGS. 9 to 12 show the same types of results as FIGS. 1 to 4 respectively, but obtained with a sample containing immature granulocytes (IG) and treated according to the invention.

[0088] The reagent and the process of the invention thus enable a specific lysis and a simultaneous staining of biological cells in a sample, in particular in a sample of human or animal blood, to be carried out in a single stage.

[0089] Cells may thus be identified and counted rapidly using an automated analysis system based on flow cytometry.

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7531542May 9, 2006May 12, 2009WyethBenzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7534796Feb 15, 2006May 19, 2009WyethImidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113Feb 15, 2006May 26, 2009Wyeth4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634Feb 15, 2006Sep 1, 2009Wyeth7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582636May 23, 2006Sep 1, 2009WyethPiperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US7696210Jun 16, 2005Apr 13, 2010WyethGonadotropin releasing hormone receptor antagonists
US7714130Jun 16, 2005May 11, 2010WyethProcesses for preparing gonadotropin releasing hormone receptor antagonists
US7745219 *Jul 21, 2004Jun 29, 2010Siemens Healthcare Diagnostics Inc.Reagent composition for the analysis of residual white blood cells in leuko-reduced blood banking products
US7892841Mar 28, 2007Feb 22, 2011Sysmex CorporationMethod and apparatus for measuring hematological sample
US7981681 *Mar 22, 2006Jul 19, 2011C2 DiagnosticsMethod for the analysis of a blood sample, and apparatus and reagent for its implementation
US8034610Apr 21, 2006Oct 11, 2011Celerus Diagnostics, Inc.Parallel processing fluidic method and apparatus for automated rapid immunohistochemistry
US9017610Apr 27, 2009Apr 28, 2015Roche Diagnostics Hematology, Inc.Method of determining a complete blood count and a white blood cell differential count
Classifications
U.S. Classification435/6.16, 435/7.21, 435/40.5
International ClassificationG01N33/50, G01N33/49, C12Q1/02, C12Q1/06
Cooperative ClassificationG01N33/5094, Y10T436/101666, Y10T436/108331, Y10T436/25125, Y10T436/107497, Y10T436/10, Y10T436/2525
European ClassificationG01N33/50D6
Legal Events
DateCodeEventDescription
Jun 24, 2002ASAssignment
Owner name: ABX, FRANCE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEFEVRE, DIDIER;VERIAC, SYLVIE;CHAMPSEIX, HENRI;REEL/FRAME:013030/0974
Effective date: 20020306